Tesamorelin side effects:
what Phase III trials found.

Across the Phase III clinical trials, six tesamorelin side effects occurred at a rate above 5% and more frequently than in placebo-treated patients. These constitute the FDA-labeled common adverse reactions and are what a typical patient should expect to possibly experience on tesamorelin therapy.

Injection site reactions. The most common tesamorelin side effect is local reaction at the injection site — erythema (redness), pruritus (itching), bruising, mild swelling, or discomfort. Reported in 20–30% of patients in the trials. These reactions are typically mild, self-limiting within 24–48 hours, and managed by rotating injection sites across the abdomen rather than injecting repeatedly into the same spot. Severe injection site reactions (requiring discontinuation) are rare. Injection site lipohypertrophy (localized fat accumulation from repeated injection) or lipoatrophy (fat loss at repeated sites) can develop with long-term use at the same site, which is why site rotation is emphasized.

Arthralgia (joint pain). Reported in roughly 13% of patients vs 6% on placebo. The joint pain is typically mild, often in the hands, wrists, or knees, and is mechanistically consistent with fluid retention in connective tissues — a known effect of elevated GH/IGF-1. Most cases are tolerable and resolve or diminish with continued therapy as tissues adapt. Occasional dose reduction (1 mg instead of 2 mg) helps in patients who find the arthralgia limiting.

Peripheral edema. Mild swelling of the lower extremities, hands, or face occurs in 8–10% of tesamorelin patients. This is a classic GH-related effect driven by sodium and water retention and is usually self-limiting within the first 4–8 weeks of therapy as the body adjusts. Persistent significant edema warrants dose reduction or discontinuation.

Myalgia (muscle pain). Reported in roughly 6% of patients, typically mild muscle aching most commonly in the arms or legs. Like arthralgia, this is usually dose-dependent and often resolves with continued use.

Pain in extremity. A distinct reporting category encompassing diffuse limb pain not clearly localized to joint or muscle. Reported in 6–7% of patients. Mechanism overlaps with arthralgia and myalgia.

Injection site pruritus. Itching at the injection site reported separately from the broader "injection site reactions" category. Frequency 6–8%. Generally mild and transient.

Tesamorelin, like all growth hormone–axis therapies, can produce modest changes in glucose metabolism. Elevated GH and IGF-1 both have complex effects on insulin sensitivity — acutely, GH is counterregulatory to insulin and can reduce peripheral glucose uptake, while IGF-1 has insulin-like effects that partially offset this. The net clinical effect of tesamorelin on glucose is generally mild but worth monitoring, particularly in patients with pre-existing insulin resistance, prediabetes, or type 2 diabetes.

In the Phase III trials, mean fasting glucose rose by approximately 2–3 mg/dL in tesamorelin patients vs placebo — a small and clinically nonsignificant change in most patients but potentially meaningful in those near glycemic thresholds. HbA1c changes were similarly small. Patients with diabetes on oral hypoglycemic agents or insulin who start tesamorelin should have their glycemic control monitored, and dose adjustments of glucose-lowering medications may occasionally be needed.

Patients without diabetes who develop elevated fasting glucose or impaired glucose tolerance during tesamorelin therapy should consider dose reduction to 1 mg daily, temporary discontinuation, or concurrent metabolic optimization (reduced refined carbohydrate intake, increased insulin-sensitizing exercise). The glucose effects typically do not progress over time and often improve as visceral fat reduction progresses — because VAT itself drives insulin resistance, so reducing it partially offsets the direct GH effect.

A theoretical concern that arises with any GH-axis therapy is whether elevated IGF-1 increases the risk of cancer. IGF-1 is a mitogen — it promotes cell proliferation — and epidemiologic studies in the general population have found weak associations between higher circulating IGF-1 levels and incidence of certain cancers (particularly prostate, breast, and colorectal cancer in some analyses). This has led to concerns that chronic IGF-1 elevation from tesamorelin or similar therapies might elevate cancer risk.

The clinical evidence for this concern with tesamorelin specifically is limited and does not show an observed increase in cancer incidence. Phase III trials and their extension studies followed patients for up to 2 years of continuous therapy and did not identify a cancer signal. Post-marketing safety data over more than a decade of approved use has not shown a disproportionate cancer risk in tesamorelin-treated populations. That said, the trials were not large enough or long enough to rule out small effects on cancer risk, and patients with known active malignancy or a history of cancer should discuss the theoretical risk with their healthcare provider before starting tesamorelin.

Importantly, tesamorelin's IGF-1 elevation is physiologic — levels rise into the upper half of the age-adjusted normal range rather than into supraphysiologic territory. This is meaningfully different from the sustained supraphysiologic IGF-1 elevation seen with direct GH injection at aggressive doses, and the cancer concern is more applicable to that pattern than to tesamorelin's pulsatile physiologic elevation.

Tesamorelin has several absolute and relative contraindications that limit who can safely use it. These are documented in the FDA prescribing information and reflect specific populations where the balance of risk and benefit is unfavorable.

Active malignancy. Tesamorelin is contraindicated in patients with active malignancy because of the theoretical IGF-1–cancer concern. GH therapy of any type is generally avoided during active cancer treatment and for a period afterward. Patients with a history of cancer in remission can sometimes use tesamorelin but only after careful risk-benefit discussion with an oncologist.

Pregnancy. Tesamorelin is contraindicated in pregnancy. GH and IGF-1 have important roles in fetal development, and exogenous disruption of the maternal GH axis during pregnancy is not well studied. Tesamorelin should be discontinued before planned pregnancy and avoided during pregnancy and breastfeeding.

Hypersensitivity. Known hypersensitivity to tesamorelin, to mannitol (an excipient in the formulation), or to any component of the reconstituted product is an absolute contraindication.

Disrupted HPA axis. Patients with hypopituitarism, pituitary tumors, pituitary surgery, head irradiation, or head trauma have a disrupted GHRH–GH axis that may not respond normally to tesamorelin. These conditions are not absolute contraindications but require specialist evaluation before starting therapy.

Critical illness. Patients in intensive care with acute critical illness should not receive tesamorelin. In this setting, even physiologic GH elevation has been associated with increased mortality in some studies, likely due to effects on inflammation and glucose metabolism.

Proliferative diabetic retinopathy or macular edema. Active, severe retinopathy is a relative contraindication because IGF-1 has been implicated in retinal vascular proliferation, and elevating it in patients with active retinopathy carries theoretical risk.

Long-term tesamorelin safety data comes from extension studies of the Phase III trials (52 weeks continuous), post-marketing surveillance, and pooled safety analyses including the Mohr et al. 2023 review. Across all sources, no new safety signals have emerged beyond those seen in the initial 26-week trials. Long-term side effects of tesamorelin appear to reflect the same profile as short-term effects — injection site reactions, arthralgia, edema — without progression in severity or novel adverse events.

Specifically, cumulative tesamorelin exposure for more than 2 years has not been associated with increased cancer incidence, acromegalic features, progression of retinopathy, or clinically significant worsening of glucose metabolism beyond baseline. IGF-1 levels remain stable in the physiologic range throughout long-term therapy — they do not progressively climb with continued dosing, reflecting the intact negative feedback from somatostatin that tesamorelin preserves by acting upstream rather than bypassing the pituitary.

Discontinuation of tesamorelin produces gradual regression of benefits — VAT rebounds over 3–6 months, IGF-1 returns to baseline within weeks — without rebound hyperglycemia or other withdrawal effects. This is consistent with the GH axis returning to its pre-treatment set point rather than being permanently altered by the intervention.